All In Biotech

Drug Trial Radar · NCT03037606

Comparison of the Effect of Rabeprazole 50 mg DDR Capsules and 20 mg Enteric-coated Tablets

Comparison of the Effect of Rabeprazole 50 mg DDR Capsules and 20 mg Enteric-coated Tablets on Intragastric and Intraesophageal Acidity

Last checked: Nov 20, 2026Latest source record: Dec 12, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Aug 1, 2017

Primary completion

Dec 1, 2018

Study completion Dec 11, 2018

Sponsor

Lead sponsor
Neutec Ar-Ge San ve Tic A.ŞIndustry
Sponsor type
Industry
First posted
Jan 31, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

It is planned to compare the efficacy and safety of rabeprazole 50 mg DDR (dual delayed release) capsules versus rabeprazole 20 mg enteric coated tablets administered once daily in patients with Gastroesophageal Reflux Disease (GERD).

Conditions

  • Gastroesophageal Reflux Disease

Interventions

  • Rabelis DDR 50 mg CapsulesDrug

    Rabelis DDR 50 mg Capsules once daily for seven days.

  • Pariet 20 mg Enteric Coated TabletsDrug

    Pariet 20 mg Enteric Coated Tablets once daily for seven days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage time of 24-hour intragastric pH >4 compared to baselineTime frame: 7 days
  2. AUC of 24-hour intragastric pH >4 compared to baselineTime frame: 7 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ege University Facult of Medicine Gastroenterology Department

    Izmir, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.